Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Human Papillomavirus Infection

Treatments: Other: Prevalence-based model

Study type: Observational

Funder types: Industry

Identifiers

NCT01702337

114420

Details and patient eligibility

About

This study compares the health and economic impact of the bivalent HPV vaccine (HPV-1) and the quadrivalent HPV vaccine (HPV-2).

Full description

This study uses a prevalence-based model (by using efficacy data from each vaccine's respective trials and published cost data for Taiwan) which estimates the differences in lesions, genital warts, cervical cancer and costs from a healthcare payer's perspective prevented between HPV-1 and HPV-2 vaccines during one year (when all women are vaccinated). It also analyses costs from a societal perspective.

Enrollment: 1 patient

Sex: Female

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Female subjects vaccinated with either HPV-1 or HPV-2 vaccines in Taiwan (hypothetical group).

Exclusion criteria

• Not applicable.

Trial design

1 participants in 2 patient groups

HPV-1 Group

Description:

Hypothetical group of women vaccinated with HPV-1 vaccine in Taiwan.

Treatment:

Other: Prevalence-based model

HPV-2 Group

Description:

Hypothetical group of women vaccinated with HPV-2 vaccine in Taiwan.

Treatment:

Other: Prevalence-based model